RCTs show the efficacy of psilocybin in the treatment of anxiety and depression symptoms, as well as improvement in HRQoL, and no serious side effects.

This research suggests that psychedelics “are the master key for unlocking lots of different critical periods.”

Administration of GH001 to a cohort of 16 patients with TRD was well tolerated and provided potent and ultra-rapid antidepressant effects.

Ketamine was associated with comparable clinical benefits, safety, and tolerability in a TAY sample as compared to a matched GA TRD sample.

We propose that feeling and behaving authentically could have a central role in explaining the positive effects of microdosing on health and wellbeing that are reported by current research.

Naturalistic psychedelic users are as likely to report an overall positive outcome and no more likely to report adverse events in group settings than in solo settings. This supports further research into PAP in group settings.

We summarize preliminary data on the efficacy of psychedelic-assisted therapy in people with anorexia nervosa, bulimia nervosa, and binge eating disorder,.

Notably, the time course of critical period reopening is proportional to the duration of acute subjective effects reported in humans.

There was a significant increase in gratitude, nature relatedness, and nature appreciation at the one-week and one-month follow-ups compared to baseline.

Evidence is now building for psychedelics' safety and efficacy in treating a range of psychiatric disorders including addiction.

Our results support the assertion that psilocybin increases the malleability of self-related processing, and diminishes shame-based and self-critical thought patterns while improving affect regulation and reducing alcohol cravings. These findings suggest that psychosocial treatments that integrate self-compassion training with psychedelic therapy may serve as a useful tool for enhancing psychological outcomes in the treatment of AUD.

Psilocybin has the potential to be a cost-effective therapy for severe depression. This depends on the level of psychological support that is given to patients receiving psilocybin and the price of the drug itself. Further data on long-term outcomes are required to improve the evidence base.

These studies provide insights into the interactions between classic psychedelics and a range of drugs, including antidepressants, antipsychotics, anxiolytics, mood stabilisers, recreational drugs and others.

The increasing popularity of psychedelic-assisted psychotherapy (PAP) has generated important discussions about the safety of psychedelic drugs.

The results indicate that any differences in the pharmacological profiles of mescaline, LSD, and psilocybin do not translate into relevant differences in the subjective experience.

Patients reported several esketamine effects with psychotherapeutic potential, such as increased openness, detachment, an interruption of negativity, and mystical-type experiences.